Depression Disorders, Major Depressive Disorder
Conditions
Keywords
Near-infrared transcranial laser therapy, Hamilton Depression rating scale, Major depressive Disorder, Clinical trial
Brief summary
Note: This registration is retained as a historical study record. Updated study information and subsequent protocol modifications are available under ClinicalTrials.gov Identifier NCT06934135, which serves as the actively maintained study registration. The Near-Infrared Transcranial Laser Therapy (NIR-TLT) is a non-invasive intervention that delivers near-infrared light to brain tissue. Photobiomodulation is believed to interact with cytochrome c oxidase, a mitochondrial enzyme involved in cellular energy metabolism, resulting in increased adenosine triphosphate (ATP) production and potential neuroprotective effects. These mechanisms may promote cellular plasticity and support improvement of depressive symptoms. This study evaluates the safety, tolerability, and potential antidepressant effects of NIR-TLT in adults with Major Depressive Disorder.
Detailed description
Study purpose: To assess and compare the effect(s) of each of the four doses of NIR-TLT on symptomatology of depression: antidepressant effect, in subjects with major depressive disorder (MDD). To assess the safety and tolerability of each dose of NIR-TLT. Compare the effect(s) of each of the four doses of NIR-TLT in brain electrophysiology. To describe the findings visualized in PET, related to the cerebral metabolism of the participants, before and after receiving the intervention under study. Study design: This protocol is a multicentered, randomized, simulated, and double-blind clinical study. This work will randomize 112 subjects into 4 equal groups: bilateral continuous wave (BCW), bilateral pulsed wave (BPW 1-2) y SHAM. All subjects, investigators (except the study statistician), and outcomes assessors will be blind to group assignment. The device operator will be aware of group assignments. All subjects will receive 3 NIR-TLT treatments per week for 6 weeks. A follow-up evaluation will be performed 2 weeks after the end of the study. The treatment will follow these specifications: wavelength 830 nm; average irradiance 54,8 mW / cm2; average fluence of 65,8 J / cm2 (consistently with parameters used in the ELATED-2 study at MGH with the device Omnilux New U), being the total Fluency delivered: 3.6 kJ (bilateral) o 1.8 kJ (unilateral), either on the subject's forehead, at or near electroencephalography sites (EEG) F3 and F4. All NIR-TLT sessions will last 20 minutes, regardless of group assignment. Study population: Patients eligible for study participation will be diagnosed with major depressive disorder (MDD) by DSM criteria. Subjects will be between 18-75 years of age (have not had 76st birthday) on the date of screening. Duration of participation: Subjects will be followed in the study for 8 weeks (a 6-week treatment period, plus 2 weeks of follow-up). The total duration of the study will be 24 months. Assessment criteria: The primary efficacy criteria is the improvement in depressive symptoms from each of the four doses of NIR-TLT. Assessed using HAMD-17, at 3 time points (visit 1, visit 9 and visit 18).
Interventions
DEVICENear-infrared Transcranial Laser Therapy
The treatment consists in exposing bilaterally the frontal brain to Transcranial Laser Therapy, which may enhance ATP production in depressed subjects.
Sponsors
Peruvian Clinical Research
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects age at screening will be between 18 and 75 years old (inclusive). 2. Diagnosis of major depressive disorder (Mini International Neuropsychiatric Interview, MINI) 3. QIDS-CR≥12 at screening 4. CGI-S ≥4 or higher, i.e., "moderately depressed" 5. Women of child-bearing potential must use a double-barrier method for birth control (e.g. condoms plus spermicide) if sexually active. 6. Subject Informed Consent obtained in writing in compliance with local regulations prior to enrollment into this study. 7. The subject is willing to participate in this study for at least 12 weeks. 8. Subjects will need to be on stable dose(s) of antidepressants (if taking any) for at least six weeks prior to enrollment.
Exclusion criteria
1. Decrease in Symptoms of Depression Questionnaire (SDQ) self-report from screening to baseline \>=30%, calculated as \[(SDQ screening-88) - (SDQ initial-88) / (SDQ screening-88)\] \>=30/100. A score of 88 is "normal" in SDQ. 2. The subject is pregnant or lactating. 3. The subject failed more than 2 adequate treatments with FDA approved antidepressants during current episode per Antidepressant Treatment Response Questionnaire (ATRQ) criteria (less than 50% decrease in depressive symptomatology). 4. Structured psychotherapy focused on treating the subject's depression is permitted if started at least 8 weeks prior to the screening visit. 5. Substance dependence or abuse in the past 3 months. 6. History of a psychotic disorder or psychotic episode (current psychotic episode per MINI assessment). 7. Bipolar affective disorder (per MINI assessment). 8. Unstable medical illness, defined as any medical illness which is not well-controlled with standard-of-care medications (e.g., insulin for diabetes mellitus). 9. Active suicidal or homicidal ideation (both intention and plan are present), as determined by Columbia-Suicide Severity Rating Scale (C-SSRS) screening. 10. The subject has a significant skin condition (i.e., hemangioma, scleroderma, psoriasis, rash, open wound or tattoo) on the subject's scalp that is found to be in proximity to any of the procedure sites. 11. The subject has an implant of any kind in the head (e.g. stent, clipped aneurysm, implantable shunt - Hakim valve). 12. Any use of light-activated drugs (photodynamic therapy) within 14 days prior to study enrollment (in US: Visudine (verteporfin) for age related macular degeneration; Aminolevulinic Acid- for actinic keratoses; Photofrin (porfimer sodium) - for esophageal cancer, non-small cell lung cancer; Levulan Kerastick (aminolevulinic acid HCl) - for actinic keratosis; 5-aminolevulinic acid (ALA)- for non-melanoma skin cancer) 13. Recent history of stroke (90 days). 14. The subject failed a device-based intervention FDA-approved for the treatment of depression, during the current episode (e.g. less than 50% decrease in depressive symptomatology with Transcranial Magnetic Stimulation). 15. History of dementia, traumatic brain injury (TBI) or any other organic neurological disorder.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the scores of the Hamilton Depression Rating Scale (HAMD-17) from baseline to week 3 and week 6. | From baseline to week 3 and week 6. | The antidepressant effects of NIR-TLT doses will be measured using the Hamilton Depression rating scale (HAM-D 17). The HAM-D 17 is a 17-item clinician rated instrument developed to quantify the severity of depression in subjects already diagnosed with this disorder. The rating of this tool will be determined in an interview with the psychiatrist, yielding a maximum score of 52. Higher scores represent greater severity of depression. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the scores of the Quick Inventory of Depressive Symptomatology-Clinician Rated Scale (QIDS-CR) from baseline to week 3 and week 6. | From baseline to week 3 and week 6. | The antidepressant effects of NIR-TLT doses will be measured using the QIDS-CR. This is a brief (16-item) clinician-rated inventory of core depressive symptoms such as sleep, depressed mood, appetite, concentration, suicidal ideation, interest, energy, psychomotor retardation, or agitation. The range score is 0 to 27. Higher scores represent greater severity of depression. |
| Changes in the scores of the Clinical Global Impressions - Severity (CGI-S) from baseline to week 3 and week 6. | From baseline to week 3 and week 6. | The antidepressant effects of NIR-TLT doses will be measured using the CGI-S. The CGI-S is one of the two components of the CGI test. This tool asks the clinician one question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. |
| Changes of electroencephalogram (EEG) espectral power from baseline to week 3 and week 6. | From baseline to week 3 and week 6. | To compare the effects of NIR-TLT doses on brain electrophysiology, changes in EEG spectral power in all spectral bands for each dose will be analyzed. The waves that will be considered are alpha, theta, and delta. For all of them, frequency and amplitude will be registered. |
| Changes in the scores of the Systemic Assessment for Treatment Emergent Events (SAFTEE-SI) from baseline to week 3 and week 6. | From baseline to week 3 and week 6. | To compare the safety and tolerability of NIR-TLT doses, mean changes in SAFTEE-SI scores will be analyzed. This is a questionnaire developed for psychiatric trials. The SAFTEE-SI allows ratings of five levels of severity and collects information about the onset, duration, pattern, judgment of attribution of cause, and action taken by the clinician when an Adverse Event happens. The range score is 0 to 128. |
| Brain metabolism effect of NIR-TLT dose (exploratory assessment) from baseline to week 6. | From baseline to week 6. | The analysis of the results obtained in the PET will be for exploratory purposes to study the brain metabolism of the participants, before and at the end of the study intervention in the 4 groups. The cortical regions that will be analyzed are the prefrontal lateral and prefrontal medial regions (right and left for both). |
Countries
Peru
Contacts
PRINCIPAL_INVESTIGATORWilliam Aguilar Rivera, Dr.
Hospital Nacional Hipolito Unanue
PRINCIPAL_INVESTIGATORBeatrice Macciotta Felices, Dr.
Clinica Vesalio
PRINCIPAL_INVESTIGATORJeff Huarcaya, Dr.
Hospital Nacional Guillermo Almenara Irigoyen
Outcome results
None listed